source
- Biogen reports mixed Alzheimer’s trial results as industry sees new startup launchesBiogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks. The weekly newsletter also highlighted the launch of two new biotech startu…
- Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit ForecastAbbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…